Your browser version may not work well with NCBI's Web applications. More information here...
1: Vestn Ross Akad Med Nauk. 2008;(7):19-24.Links

[RAMS academician I. V. Tarasevich is a leader of development of combined inactivated vaccine against Q-fever]

[Article in Russian]

Short information about significance of Q-fever in human pathology is represented. Necessity of vaccination is proved. The row of vaccines, developed in Czechoslovakia and Romania and identified as small-effective, was considered. Live vaccine from M-44 strain, was made in USSR, still remains in Russia. However, experimental data of American and Russian authors showed persistency of Q-fever agents in vaccinated animals, abortions and other pathology. WHO recommended declining to use live vaccines. Inactivated corpuscular combined vaccine against Q-fever was development under leadership of I. V. Tarasevich. The method of vaccine production is protected by industrial patent #2094057 from 31.01.94, concomitant studies--by 9 author's certificates. The vaccine is harmless, are actogenic, and high immunogenic after single injection. Antibodies of vaccinated persons remain more than in 75% during one year. The vaccine assists in resolving of actual problems of fight against Q-fever.

Personal Name as Subject:
Tarasevich IV

PMID: 18756779 [PubMed - indexed for MEDLINE]